Journal of the Neurological Sciences
Volume 203 , Pages 57-65 , 15 November 2002

Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia

  • Raymond D Pratt

      Affiliations

    • Corresponding Author InformationTel.: +1-201-287-2161; fax: +1-201-692-9183
    • Potential conflict of interest disclosure: Raymond D. Pratt is an employee of Eisai Inc. These studies were supported by Eisai Inc.

References 

  1. Nyenhuis DL, Gorelick PB. Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. J. Am. Geriatr. Soc. 1998;46:1437–1448
  2. Rocca WA, Hofman A, Brayne C, et al.  The prevalence of vascular dementia in Europe: facts and fragments from 1980–1990 studies. EURODEM Prevalence Research Group. Ann. Neurol. 1991;30:817–824
  3. Andersen K, Launer LJ, Dewey ME, et al.  Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. EURODEM Incidence Research Group. Neurology. 1999;53:1992–1997
  4. Meyer JS, Rauch GM, Rauch RA, et al.  Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann. N.Y. Acad. Sci. 2000;903:411–423
  5. Hachinski VC, Iliff LD, Zilhka E, et al.  Cerebral blood flow in dementia. Arch. Neurol. 1975;32:632–637
  6. Roman GC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S69–S80
  7. Erkinjuntti T. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int. J. Clin. Pract., Suppl. 2001;14–23
  8. Sachdev PS, Brodaty H, Looi JC. Vascular dementia: diagnosis, management and possible prevention. Med. J. Aust. 1999;170:81–85
  9. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S115–S123
  10. Sakurada T, Alufuzoff I, Winblad B, et al.  Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. Brain Res. 1990;521:329–332
  11. Waller SB, Ball MJ, Reynolds MA, et al.  Muscarinic binding and choline acetyltransferase in postmortem brains of demented patients. Can. J. Neurol. Sci. 1986;13(Suppl. 4):528–532
  12. Gottfries CG, Blennow K, Karlsson I, et al.  The neurochemistry of vascular dementia. Dementia. 1994;5:163–167
  13. Tohgi H, Abe T, Kimura M, et al.  Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural Transm. 1996;103:1211–1220
  14. Swartz RH, Black SE. How common is vascular compromise of cholinergic white matter pathways in a memory clinic sample?. Presentation at the In: 2nd International Congress on Vascular Dementia, January, Salzburg, Austria. 2002;
  15. Roman GC, Tatemichi TK, Erkinjuntti T, et al.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260
  16. Kalaria RN, Ballard CG, Ince PG, et al.  Multiple substrates of late-onset dementia: implications for brain protection. Novartis Found. Symp. 2001;235:49–60
  17. Sugimoto H, Iimura Y, Yamanishi Y, et al.  Synthesis and structure–activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)-methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 1995;38:4821–4829
  18. Rogers SL, Farlow MR, Doody RS, et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136–145
  19. Burns A, Rossor M, Hecker J, et al.  The effects of donepezil in Alzheimer's disease—results from a multinational trial. Dement. Geriatr. Cogn. Disord. 1999;10:237–244
  20. Winblad B, Engedal K, Soininen H, et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489–495
  21. Mohs RC, Doody RS, Morris JC, et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481–488
  22. Feldman H, Gauthier S, Hecker J, et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613–620
  23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198
  24. World Medical Association Declaration of Helsinki . Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925–926
  25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's Disease. Am. J. Psychiatr. 1984;14:1356–1364
  26. Knopman DS, Knapp MJ, Gracon SI, et al.  The clinician interview-based impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994;44:2315–2321
  27. Kittner B, De Deyn PP, Erkinjuntti T. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Ann. N.Y. Acad. Sci. 2000;903:535–541
  28. Roman G. Diagnosis of vascular dementia and Alzheimer's disease. Int. J. Clin. Pract., Suppl. 2001;9–13
  29. Desmond DW, Erkinjuntti T, Sano M, et al.  The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis. Assoc. Disord. 1999;13:S21–S29
  30. Cannata AP, Alberoni M, Franceschi M, et al.  Frontal impairment in subcortical ischemic vascular dementia in comparison to Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2002;13:101–111
  31. Wade JP, Mirsen TR, Hachinski VC, et al.  The clinical diagnosis of Alzheimer's disease. Arch. Neurol. 1987;44:24–29
  32. Kumar V, Anand R, Messina J, et al.  An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 2000;7:159–169
  33. Wilcock GK, Whitehead A, Grimley Evans J, et al.  Donepezil: a meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease. Presentation at the In: 53rd Annual Meeting of the American Academy of Neurology, May, Philadelphia, USA. 2001;
  34. Inzitari D, Lamassa M, Carlucci G, et al.  The use of nimodipine in the setting of vascular dementia. Presentation at the In: 2nd International Congress on Vascular Dementia, January, Salzburg, Austria. 2002;
  35. Pantoni L, Rossi R, Inzitari D, et al.  Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J. Neurol. Sci. 2000;175:124–134
  36. Meyer JS, Chowdhury MH, Quach M. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. Presentation at the In: 2nd International Congress on Vascular Dementia, January, Salzburg, Austria. 2002;
  37. Fischer P, Gatterer G, Marterer A, et al.  Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. Acta Psychiatr. Scand. 1990;81:551–553
  38. Erkinjuntti T, Kurz A, Gauthier S, et al.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283–1290

PII: S0022-510X(02)00266-6

Journal of the Neurological Sciences
Volume 203 , Pages 57-65 , 15 November 2002

Article Tools

* Image Usage & Resolution